Introduction {#sec1-1}
============

One of the most frequent and debilitating complications of cancer is the involvement of the nervous system, with nearly 45% of these patients requiring evaluation of a neurological problem. Neurological complications are the most common reason for emergency admissions of patients with cancer as well as the most common and primary reason for admission, besides chemotherapy administration.\[[@ref1]\] Most studies dealing with this subject have been conducted in oncology settings, with analysis of the neurological referrals that may result in an under-reporting of neurological manifestations in cancer patients. It has been reported that approximately 15% of the patient population in an oncology centre was seen by a neurologist.\[[@ref2][@ref3]\] The National Cancer Registry in India was set up in 1981 and as late as 2009 there was no mention of a neuro-oncology society.\[[@ref4][@ref5]\] This is in contrast to the Netherlands, where a neuro-oncology register (NOR) was established nearly three decades ago and in the USA where a law was passed in 2004 making the reporting of nervous system tumours compulsory at a national level.\[[@ref6][@ref7]\] It has been observed that nearly one-third of patients seek neurological consultation for brain metastasis without any prior malignancy.\[[@ref8][@ref9]\] The clinical presentations in such patients may vary from subtle hypoactive delirium to quadriparesis and any delay in diagnosis may be catastrophic.\[[@ref10][@ref11]\]

The objective of our research was to study the clinical, radiological and histopathological spectrum of patients presenting with a neurological complaint to a neurology specialist, as the first manifestation of an underlying malignancy.

Materials and Methods {#sec1-2}
=====================

This was a prospective observational study conducted in the Department of Neurology, King George\'s Medical University, Lucknow, from January 2015 to July 2016. This study was approved by the Institutional Ethics Committee (IEC). Written informed consent was obtained from each subject or their legal guardian, prior to enrolment.

Inclusion criteria {#sec2-1}
------------------

All patients provisionally diagnosed with either primary or secondary malignancies, based on clinical, radiological and/or histopathological features, were included in the study.

Exclusion criteria {#sec2-2}
------------------

All patients below the age of 18 years or with a diagnosed malignancy were excluded.

Evaluation {#sec2-3}
----------

All included patients underwent a detailed clinical evaluation followed by imaging relevant to each case. All enrolled patients were subjected to routine blood tests. Patients with suspected metastases underwent further work up directed at finding the primary site of origin. This included a detailed urological and gynaecological examination, contrast-enhanced computed tomography (CECT) of the chest/abdomen (as indicated), radionuclide scan, FDG-PET, estimation of tumour markers (such as prostate-specific antigen, carcino-embryonic antigen and alpha-fetoprotein), serum immunoelectrophoresis and histopathological confirmation (as feasible) with the biopsy of the relevant tissue.

Neuroimaging {#sec2-4}
------------

Brain/spine magnetic resonance imaging (MRI) was performed on a Sigma Excite 1.5 Tesla scanner (General Electric Medical Systems, Milwaukee, WI, USA). An experienced neuroradiologist blindly reviewed the MRI scans in terms of lesion characteristics on different sequences, perilesional oedema, contrast-enhancement, necrosis and mass effect.

Histopathological examination {#sec2-5}
-----------------------------

Histopathology slides, whenever available, were examined independently by an expert neuro/oncopathologist and in relevant cases, immunohistochemistry staining was also performed.

Diagnostic categories {#sec2-6}
---------------------

Primary malignancies were provisionally diagnosed based on findings from their characteristic imaging while metastases were diagnosed on the basis of typical MRI findings of circumscribed contrast-enhancing lesions with disproportionate perilesional oedema and mass effect along with evidence of malignancy at another site. These cases were diagnosed as 'definite' or 'histopathologically proven' cases \[[Figure 1](#F1){ref-type="fig"}\].

![Parasagittal T2W sequence of MRI of the brain (a) shows mixed intensity space occupying lesions involving the right frontoparietal and subcortical areas with moderate to severe perilesional edema, with relatively homogeneous GAD enhancement (b). Axial contrast-enhanced CT of the thorax (c) depicts an ill-defined heterogeneously enhancing soft tissue in the posterior segment of the right upper lobe with spiculated margins suggestive of a neoplastic etiology. Smear of CT-guided aspirated material (d) shows a papillaroid cluster and singly lying cells with moderate sized, round to oval hyperchromatic nuclei, and moderate amount of amphophilic cytoplasm with few mucin vacuoles (arrows), suggestive of a non-small cell lung carcinoma. (May Grunwald Giemsa, x200)](JFMPC-8-3726-g001){#F1}

'Probable' or 'imaging' diagnoses of primary nervous system malignancies were based on neuroradiological features when the biopsy was not possible. The lesions were classified as extra-axial if they had a majority of these imaging features (cerebrospinal fluid cleft between brain and lesion, vessels interposed between brain and lesion, cortex between mass and oedematous white matter, dura (meninges) between (epidural) mass and brain). The rest were classified as intra-axial.

The origin of secondary malignancies were diagnosed as 'probable' or termed 'imaging diagnosis' if one of the following was noted: an abnormal CT scan (chest or abdomen), bone scan or positron emission tomography (PET) scan, suggesting the primary site of origin for nervous system metastasis, and the systemic workup being otherwise unremarkable and histopathological diagnosis were not possible. Presumptive diagnoses made after imaging were revised if a biopsy was possible and histopathological confirmation was obtained.

Referrals {#sec2-7}
---------

Based on the final diagnosis, patients were referred to the team of neurosurgery, radiation oncology and surgical oncology for further management.

Statistical analysis {#sec2-8}
--------------------

The statistical analysis was performed using the Statistical Package for Social Sciences, Version 16.0 for Windows (SPSS, Chicago, IL). Statistical significance was defined at a *P* value of \<0.05 and wherever analysis was done it was a 2-tailed analysis. Categorical variables were expressed as percentages while continuous variables were expressed as mean ± SD. Chi-square test was used to compare proportions; independent sample *t*-test/ANOVA was used to compare means.

Results {#sec1-3}
=======

There were a total of 4893 admissions to the department of neurology, of which 155 patients were enrolled.

The mean age of the patients was 47.19 ± 17.08 years with 87 (56%) male patients. The mean duration of the presentation was 134.17 ± 24.90 days. Headache (47.7%) was the most common symptom followed by back pain (29.7%). The most common motor symptom was paraparesis (27.7%) followed by hemiparesis (21.1%). Sensory loss in one form or the other was noticed in 40.6% of the patients. Patients were graded on their disability based on the Modified Barthel Index (MBI) with a score of ≤12 (severe) in 39 patients (25.2%) and \>12 in 116 patients (74.8%). The baseline characteristics of the cohort have been detailed in [Table 1](#T1){ref-type="table"}.

###### 

Baseline characteristics of the cohort

  Variables                              Values
  -------------------------------------- ----------------------
  Age in years (Mean±SD)                 47.19±17.08
  Sex                                    87
   Male                                  (56.1%)
   Female                                68 (43.9%)
  Mean duration of presentation (days)   134.17±24.90
  Clinical Features                      
   Pain                                  
   Headache                              74 (47.7%)
   Back pain                             46 (29.7%)
   Neck pain                             13 (8.4%)
   Pain in a limb                        33 (21.3%)
  Weakness                               
   Hemiparesis                           33 (21.1%)
   Paraparesis                           43 (27.7%)
   Quadriparesis                         16 (10.3%)
   Monoparesis                           03 (1.9%)
   Vomiting                              42 (27.1%)
   Sensory loss                          63 (40.6%)
   Gait abnormality                      79 (51.0%)
   Altered sensorium                     40 (25.8%)
   Seizures                              30 (19.4%)
   Speech abnormality                    24 (15.5%)
   Visual disturbances                   15 (9.7%)
   Cranial nerve involvement             33 (21.3%)
   Movement disorders                    0 (0.0%)
   Sphincter involvement                 54 (34.8%)
  Disability on admission                MBI \>12=116 (74.8%)
                                         MBI ≤12=39 (25.2%)
  Site of involvement                    
   Brain                                 77 (49.7%)
   Spinal cord                           45 (29.0%)
   Plexus/Radicles                       23 (14.8%)
   Nerve                                 06 (3.9%)
   Neuromuscular junction                04 (2.6%)
   Skeletal                              39 (25.2%)
   Multiple sites                        37 (23.9%)
  Origin                                 
   Primary                               75 (48.4%)
   Secondary                             80 (51.6%)
  MRI Characteristics                    
   Intra-axial                           92 (59.4%)
   Extra-axial                           59 (38.1%)
   Both                                  05 (2.5%)
  Biopsy proven                          59 (38.1%)

The most common site involving the neuraxis was the brain (49.7%) followed by the spinal cord (29.0%). Nearly 24% of the patients had multiple sites of involvement along the neuraxis as well as multiple lesions within the same site. Primary malignancies were seen in 78 cases (50.7%) while secondary malignancies were noted in 77 cases (49.3%). MRI revealed intra-axial involvement in 92 (59.4%) cases and extra-axial involvement in 59 (38.1%) cases with 5 cases having both intra- as well as extra-axial involvement. Histopathological confirmation following biopsy could be obtained in 59 patients (38.1%) \[[Table 2](#T2){ref-type="table"}\].

###### 

Characteristics of lesions based on site of involvement

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                                  Brain (*n*=77)                              Spinal cord (*n*=45)             Plexus\*/Root (*n*=23)                   Nerve (*n*=6)                  NMJ
  ----------------------------------------- ------------------------------------------- -------------------------------- ---------------------------------------- ------------------------------ -------------
  Age                                       46.94±17.09                                 46.96±17.81                      51.87±14.93                              44.67±15.89                    36.25±3.15

  Sex                                                                                                                                                                                            

   Males                                    43 (55.8%)                                  27 (60.0%)                       09 (39.1%)                               05 (83.3%)                     03 (75.0%)

   Females                                  34 (44.2%)                                  18 (40.0%)                       14 (60.9%)                               01 (16.7%)                     01 (25.0%)

  Origin                                                                                                                                                                                         

   Primary                                  35 (45.5%)                                  20 (44.4%)                       09 (39.1%)                               02 (33.3%)                     00 (0.0%)

   Secondary                                42 (54.5%)                                  25 (55.6%)                       14 (60.9%)                               04 (66.6%)                     04 (100.0%)

  MRI Characteristics                                                                                                                                                                            

   Intra-axial                              50 (64.9%)                                  09 (20.0%)                       00 (0.0%)                                00 (0.0%)                      00 (0.0%)

   Extra-axial                              24 (31.2%)                                  33 (73.3%)                       23 (100%)                                06 (100%)                      04 (100.0%)

   Both                                     03 (3.9%)                                   03 (6.7%)                                                                                                

  Biopsy proven                             26 (33.7%)                                  16 (35.6%)                       12 (52.2%)                               05 (83.3%)                     02 (50.0%)

  Pathological diagnosis                    Adenocarcinoma lung (7)\                    Multiple Myeloma (7)\            Adenocarcinoma lung (2)\                 Multiple myeloma (3)\          Thymoma (2)
                                            SCC (3)\                                    Unknown (4)\                     Adenocarcinoma breast (2)\               Neurofibroma (1)\              
                                            Bronchoalveolar carcinoma (2)\              Schwannoma (2)\                  Transitional cell carcinoma (2)\         Adenoid cystic carcinoma (1)   
                                            Infiltrating ductal papilloma (2) breast\   Meningothelial meningioma (1)\   Adenocarcinoma prostate (1)\                                            
                                            Adenocarcinoma prostate (1)\                NSCLC (1)\                       Adenocarcinoma Colon (1)\                                               
                                            Anaplastic ependymoma (1)\                  Undifferentiated carcinoma (1)   Renal cell carcinoma (1) (Chromophobe)                                  
                                            Chordoma (1)\                                                                                                                                        
                                            Follicular ca thyroid (2)\                                                                                                                           
                                            NSCLC (2)                                                                                                                                            

  PDC (2)                                                                               Squamous cell ca cervix (1)                                                                              

  GBM (2)                                                                               Leiomyosarcoma (1)                                                                                       

  Craniopharyngioma (1)                                                                 Multiple myeloma (1)                                                                                     

  Imaging diagnosis                         GBM (14) Schwannoma (4)                     Schwannoma (3)\                  \-                                       \-                             Thymoma (4)
                                                                                        Meningioma (9)                                                                                           

  Cavernous angioma (2)                                                                                                                                                                          

  Chordoma (1)                                                                                                                                                                                   

  DNET (1)                                                                                                                                                                                       

  Epidermoid (1)                                                                                                                                                                                 

  Lymphoma (1)                                                                                                                                                                                   

  Medulloblastoma (2)                                                                                                                                                                            

  Meningioma (4)                                                                                                                                                                                 

  Macroadenoma (4)                                                                                                                                                                               

  SEGCA (2)                                                                                                                                                                                      

  Intracranial metastases (single) (8)                                                                                                                                                           

  Intracranial metastases (multiple) (27)                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Brachial plexus (2), Lumbosacral plexus (21)

Brain {#sec2-9}
-----

The mean age was 46.94 ± 17.09 years with 55.8% of patients being male and the rest female. The primary malignancy group constituted 45.5% of these patients while 54.5% fell into the secondary malignancies group. Fifty (64.9%) of these lesions were intra-axial and 24 patients (31.2%) had extra-axial lesion; 3 patients (3.9%) had both type of lesions. Histopathological confirmation could be achieved in 26 patients (33.7%) with the most common malignancy being adenocarcinoma lung.

Spinal cord {#sec2-10}
-----------

The mean age was similar to the 'brain' group (46.96 ± 17.81 years) with 60% males and 40% females. Twenty (44.4%) patients had a primary malignancy and 25 (55.6%) patients were classified in the secondary malignancies group. In contrast to the 'brain' group, extra-axial lesions were found to be in a higher proportion (73.3%) as compared to intra-axial lesions (20.0%). However, in 16 patients (35.6%), the diagnosis could be confirmed histopathologically.

Plexus/nerve root {#sec2-11}
-----------------

Two patients had brachial plexus involvement while the rest (21 patients) had involvement of the lumbosacral plexus. The mean age was higher as compared to the brain and spinal cord lesions (51.87 ± 14.93 years) with 60.9% females and 39.1% males. Secondary malignancies were also higher in this group (60.9%) as compared to the primary ones (39.1%). Twelve of these lesions were proven by histopathology.

Nerve {#sec2-12}
-----

Five patients were males (83.3%) and one female (16.7%). Histopathology revealed two of these having a primary involvement (neurofibroma and adenoid cystic carcinoma) and the rest of them having multiple myeloma with chronic inflammatory demyelinating polyneuropathy (CIDP).

Primary versus Secondary malignancies {#sec2-13}
-------------------------------------

The mean age of patients with secondary malignancies (55.05 ± 13.05 years) was significantly higher (P-value \<0.001, 95% CI: - 20.644 -10.991) than those with primary involvement (39.23 ± 17.06 years). Severe disability (MBI ≤12) at the time of admission was seen in 32 patients (41.0%) with secondary malignancies, as against 7 patients (9.1%) with a primary malignancy.

On MRI scanning the primary group had 44% intra-axial and 56% extra-axial lesions, whereas in the secondary group extra-axial involvement was proportionally higher (62.5% extra-axial and 32.5% intra-axial). Moreover, 5% of patients in the secondary group had both intra-axial and extra-axial involvement.

The most common imaging diagnosis in the primary group was glioma/glioblastoma multiforme (16), followed closely by meningioma (13). In the secondary group, the most common imaging diagnosis was multiple intracranial metastases (27) followed by multiple vertebral metastases (26). A single intracranial metastatic lesion was seen in eight patients. Histopathological confirmation rate was higher in the secondary group (i.e. 57.7% versus 18.2% in the primary group).

In patients with primary brain tumours, a total of 12 definite histopathologically confirmed diagnoses were obtained. Two patients who presented with myasthenia gravis had a thymoma on chest CT and another two who had a solitary plasmacytoma in the cervical vertebral lamina and spinous process were also included in this list.

The most common histopathological diagnosis in the secondary malignancies group was adenocarcinoma lung and multiple myeloma (ten patients each). Overall, the lung was the most common tissue of primary origin of metastases (15; 10 adenocarcinomas, 3 NSCLC, 2 bronchoalveolar) followed by plasma cells and the prostate. Other prominent diagnoses included adenocarcinoma breast, adenocarcinoma prostate and poorly/undifferentiated carcinoma. The details of diagnoses are listed in [Table 3](#T3){ref-type="table"}. Ten (6.45%) patients remained undiagnosed \[[Table 4](#T4){ref-type="table"}\].

###### 

Comparison between primary and secondary lesions

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                         Primary                             Secondary                                                            *P*
  --------------------------------- ----------------------------------- -------------------------------------------------------------------- ---------
  Age (in years)                    39.23±17.06                         55.05±13.05                                                          \<0.001

  Sex                                                                                                                                        

   Male                             38 (50.7%)                          49 (61.3%)                                                           1.866

   Female                           37 (49.3%)                          31 (38.7%)                                                           

  Mean duration of illness (days)   169.10±426.51                       99.69±101.53                                                         0.168

  Clinical features                                                                                                                          

  Pain                                                                                                                                       

   Headache                         39 (50.6%)                          35 (44.9%)                                                           0.518

   Backache                         10 (13.0%)                          36 (46.2%)                                                           20.424

   Neck pain                        06 (7.8%)                           07 (9.0%)                                                            0.070

   Pain in a limb                   09 (11.7%)                          24 (30.8%)                                                           8.419

  Weakness                                                                                                                                   

   Hemiparesis                      15 (19.5%)                          18 (23.1%)                                                           5.334

   Paraparesis                      17 (22.1%)                          26 (33.3%)                                                           

   Quadriparesis                    11 (14.3%)                          05 (6.4%)                                                            

   Monoparesis                      01 (1.3%)                           02 (2.6%)                                                            

   Vomiting                         21 (27.3%)                          21 (26.9%)                                                           0.002

   Sensory loss                     33 (42.9%)                          30 (38.5%)                                                           0.310

   Gait abnormality                 37 (48.1%)                          42 (53.8%)                                                           0.521

   Altered sensorium                18 (23.4%)                          22 (28.2%)                                                           0.472

   Seizures                         12 (15.6%)                          18 (23.1%)                                                           1.394

   Speech abnormality               13 (16.9%)                          11 (14.1%)                                                           0.229

   Visual disturbances              13 (16.9%)                          02 (2.6%)                                                            9.089

   Cranial nerve involvement        26 (33.8%)                          07 (9.0%)                                                            14.212

   Movement disorders               00 (0.0%)                           00 (0.0%)                                                            \-

   Sphincter involvement            26 (33.8%)                          28 (35.9%)                                                           0.078

  Disability on admission                                                                                                                    

   MBI (0-12)                       07 (9.1%)                           32 (41.0%)                                                           20.99

   MBI (13-20)                      70 (90.9%)                          46 (59.0%)                                                           

  Site of involvement Brain         42 (56.0%)                          35 (43.8%)                                                           1.450

  Spinal cord                       20 (26.7%)                          25 (31.2%)                                                           0.695

   Plexus                           07 (9.3%)                           16 (20.0%)                                                           1.202

   Nerve/Radicles                   02 (2.7%)                           04 (5.0%)                                                            0.667

   Neuromuscular junction           03 (3.9%)                           01 (1.2%)                                                            1.053

   Skeletal                         02 (2.7%)                           37 (46.3%)                                                           41.371

   Multiple sites                   05 (6.7%)                           32 (40.0%)                                                           25.426

  MRI Characteristics                                                                                                                        

   Intra-axial                      33 (44.0%)                          26 (32.5%)                                                           4.998

   Extra-axial                      42 (56.0%)                          50 (62.5%)                                                           

   Both                             00 (0.0%)                           04 (5.0%)                                                            

  Biopsy proven                     12 (16.0%)                          47 (58.7%)                                                           25.628

  Pathological diagnosis            Glioblastoma multiformae (2)\       Adenocarcinoma lung (10)\                                            
                                    Thymoma (2)\* Plasmacytoma (2)\#\   Multiple myeloma (10)\                                               
                                    Anaplastic ependymoma (1)\          Adenocarcinoma prostate (5)\                                         
                                    Craniopharyngioma (1)\              Adenocarcinoma breast (4)\                                           
                                    Chordoma (1)\                       Squamous cell carcinoma (3) Poorly/undifferentiated carcinoma (3)\   
                                    Leiomyosarcoma (1)\                 Non-small cell lung carcinoma (3)\                                   
                                    Meningothelial meningioma (1)\      Bronchoalveolar ca (2)\                                              
                                    Low grade glioma (1)\               Transitional cell ca (2)\                                            
                                    Adenoid cystic carcinoma (1)        Follicular ca thyroid (2)\                                           
                                                                        Insular ca thyroid (1)\                                              
                                                                        Adenoca colon (1)\                                                   
                                                                        Renal cell carcinoma (Chromophobe cell type) (1)                     

  Imaging diagnosis                 GBM (16)\                           Vertebral metastases (26)\                                           
                                    Meningioma (13)\                    Intracranial metastases (single) (8)\                                
                                    Schwannoma (7)\                     Intracranial metastases (multiple) (27)                              
                                    Ependymoma (6)\                                                                                          
                                    Neurofibroma (4)\                                                                                        
                                    Macroadenoma (4) Thymoma (3)                                                                             

                                    Cavernous angioma (2)\                                                                                   
                                    Plasmacytoma (2)\                                                                                        
                                    SEGCA (2) Craniopharyngioma (1)\                                                                         
                                    Chordoma (1)\                                                                                            
                                    DNET (1)\                                                                                                
                                    Epidermoid (1)\                                                                                          
                                    Ewings sarcoma (1)\                                                                                      
                                    Lymphoma (1)\                                                                                            
                                    Medulloblastoma (1)                                                                                      
  ----------------------------------------------------------------------------------------------------------------------------------------------------

\*Patients with Myasthenia Gravis, \#Solitary cervical vertebral lesion

###### 

Comparison between intra-axial and extra-axial lesions

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                   Intra-axial                                Extra-axial                                              Both                                        *P*
  ------------------------------------------- ------------------------------------------ -------------------------------------------------------- ------------------------------------------- --------
  Age in years (mean +/- SD)                  45.22±17.79                                47.98±16.81                                              58.25±4.71                                  0.266

  Sex                                                                                                                                                                                         

   Male                                       34                                         50                                                       03                                          0.751

   Female                                     25                                         42                                                       01                                          

  Clinical features                                                                                                                                                                           

  Pain                                                                                                                                                                                        

   Headache                                   49 (83.1%)                                 21 (22.8%)                                               04 (100%)                                   56.753

   Backache                                   02 (3.4%)                                  40 (43.5%)                                               04 (100%)                                   37.410

   Neck pain                                  03 (5.1%)                                  10 (10.9%)                                               04 (100%)                                   1.941

   Pain in a limb                             01 (1.7%)                                  29 (31.5%)                                               03 (75%)                                    26.152

  Weakness                                                                                                                                                                                    

   Hemiparesis                                25 (42.7%)                                 07 (7.6%)                                                01 (25%)                                    42.031

   Paraparesis                                03 (5.1%)                                  37 (40.2%)                                               03 (75%)                                    35.455

   Quadriparesis                              07 (11.9%)                                 09 (9.8%)                                                00 (00%)                                    17.650

   Monoparesis                                01 (1.7%)                                  02 (2.2%)                                                00 (00%)                                    4.560

   Vomiting                                   30 (50.8%)                                 09 (9.8%)                                                03 (75%)                                    44.952

   Sensory loss                               13 (22.0%)                                 46 (50.0%)                                               04 (100%)                                   33.383

   Gait abnormality                           24 (40.7%)                                 52 (56.5%)                                               03 (75%)                                    34.622

   Altered sensorium                          31 (52.5%)                                 06 (6.5%)                                                03 (75%)                                    0.853

   Seizures                                   25 (42.4%)                                 04 (4.3%)                                                01 (25%)                                    1.314

   Speech abnormality                         22 (37.3%)                                 02 (2.2%)                                                00 (00%)                                    \-

   Visual disturbances                        07 (11.9%)                                 08 (8.7%)                                                00 (0.0%)                                   3.023

   Cranial nerve                              14 (23.7%)                                 19 (20.7%)                                               00 (0.0%)                                   

   involvement                                00 (0.0%)                                  00 (0.0%)                                                00 (0.0%)                                   

   Movement disorders Sphincter involvement   19 (32.2%)                                 32 (34.8%)                                               03 (75%)                                    

  Disability on admission                                                                                                                                                                     

   MBI (0-12)                                 17 (28.8%)                                 20 (21.7%)                                               02 (50%)                                    2.301

   MBI (13-20)                                42 (71.2%)                                 72 (78.3%)                                               02 (50%)                                    

  Site of involvement                                                                                                                                                                         

   Brain                                      50 (84.7%)                                 24 (26.1%)                                               03 (75%)                                    50.531

   Spinal cord                                09 (15.3%)                                 33 (35.9%)                                               03 (75%)                                    11.626

   Plexus                                     00 (0.0%)                                  06 (6.5%)                                                00 (00%)                                    4.274

   Nerve/Radicles                             00 (0.0%)                                  04 (4.3%)                                                00 (100%)                                   2.812

   Neuromuscular junction                     00 (0.0%)                                  35 (38.0%)                                               04 (100%)                                   39.842

   Skeletal                                   07 (11.9%)                                 26 (28.3%)                                               04 (100%)                                   18.413

   Multiple sites                                                                                                                                                                             

  Origin                                                                                                                                                                                      

   Primary                                    33 (55.9%)                                 44 (47.8%)                                               00 (00%)                                    4.998

   Secondary                                  26 (44.1%)                                 48 (52.2%)                                               04 (100%)                                   

  Biopsy proven                               18 (30.5%)                                 40 (43.5%)                                               01 (25%)                                    2.862

  Pathological diagnosis                      Adenocarcinoma lung (4)\                   Adenocarcinoma lung (4)\                                 Adenocarcinoma lung (2)\                    
                                              Adenocarcinoma prostate (4)\               Multiple myeloma (4) Undifferentiated carcinoma (2)\     Transitional cell\                          
                                              Adenocarcinoma breast (2)\                 Non-small cell lung carcinoma (2) Bronchoalveolar\       carcinoma (1)\                              
                                              Squamous cell carcinoma (1)\               carcinoma (2) Follicular ca thyroid (2)\                 Unknown (1)                                 
                                              Transitional cell carcinoma (1)\           Adenocarcinoma prostate (1)\                                                                         
                                              Anaplastic ependymoma (1)                  Chordoma (1)                                                                                         

                                                                                         Craniopharyngioma (1)\                                                                               
                                                                                         Chromophobe cell RCC (1)\                                                                            
                                                                                         Leiomyosarcoma (1)\                                                                                  
                                                                                         Infiltrating ductal papilloma (1)\                                                                   
                                                                                         Meningothelial meningioma (1)\                                                                       
                                                                                         Ductal carcinoma breast (1)\                                                                         
                                                                                         Thymoma (1)\                                                                                         
                                                                                         PDC (1) SCC invasive large cell keratinizing type (1)\                                               
                                                                                         Adenocarcinoma colon (1)\                                                                            
                                                                                         Adenoid cystic carcinoma (1)                                                                         

  Imaging diagnosis                           Intracranial metastases (single) (4)\      Vertebral metastases (26)\                               Intracranial and vertebral metastases (4)   
                                              Intracranial metastases (multiple) (21)\   Meningioma (13)\                                                                                     
                                              GBM (16)\                                  Schwannoma\                                                                                          
                                              Ependymoma (7)\                            1) Brachial plexus schwannoma (1)\                                                                   
                                              Cavernous angioma (2)\                     2) Acoustic schwannoma (6)\                                                                          
                                              DNET (2)\                                  Paravertebral mass (5)\                                                                              
                                              SEGCA (2)\                                 Pituitary macroadenoma (4)\                                                                          
                                              Medulloblastoma (2)\                       Neurofibroma (4)\                                                                                    
                                              Radiation myelitis (1)                     Thymoma (3)\                                                                                         
                                                                                         Plasmacytoma (2)\                                                                                    
                                                                                         Epidermoid (1)\                                                                                      
                                                                                         Ewings sarcoma (1)\                                                                                  
                                                                                         Cavernous sinus lymphoma (1)                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Headache, hemiparesis, seizures, speech abnormality, altered sensorium and vomiting (*P* \< 0.001) were seen in a considerably higher proportion in the intra-axial group whereas back pain, pain radiating to a limb, paraparesis and sensory loss (*P* \< 0.001) were seen more frequently in the extra-axial group.

Discussion {#sec1-4}
==========

Out of a total of 4893 patients admitted, 155 patients were enrolled and evaluated during the study period of 2 years. The mean duration of symptoms prior to diagnosis in our study was around 4 months; patients with spinal cord compression showed a shorter duration at a median of 2 months (range 5 days to 2 years).\[[@ref12]\] Headache, back pain, and paraparesis were the most common presenting features. The brain was the most common site of involvement. Primary malignancies accounted for nearly 51% of cases with the remaining cases being secondary malignancies. The age of patients with secondary malignancies was significantly higher than of those belonging to the primary group. About 60% of cases were found to be intra-axial on MRI scanning, the rest being extra-axial. The most common imaging diagnosis was glioblastoma multiforme (primary malignancies group) and multiple intracranial metastases (secondary malignancies group). Histopathological confirmation was obtained in almost one-third of cases with the most common diagnoses being adenocarcinoma lung and multiple myeloma. The most common primary tissue of origin of metastases was the lung.

Clouston *et al.* in their study found headache, back pain and altered sensorium to be the most common symptoms in cancer patients having neurological complications. In addition to these, we found weakness (paraparesis, hemiparesis, quadriparesis and monoparesis) to be one of the leading initial manifestations of systemic malignancy. They also reported that 33% of patients with cancer, presenting with undiagnosed back pain, harbour an epidural metastasis.\[[@ref3]\] Rodichok *et al.* and Ruff and Lanska, however, reported a higher incidence of epidural metastases in cancer patients with back pain (57% and 43%, respectively).\[[@ref13][@ref14]\] In our study, 43.5% of patients presenting with back pain were diagnosed having extra-axial lesions. Le chevalier *et al.* reported 58% of their patients presenting with motor deficits.\[[@ref15]\] The high incidence of motor weakness in patients with a malignancy suggests that most primary care physicians tend to treat pain as a trivial symptom and patients are referred late to a specialised centre.

In our study, we noted that a high number of patients with malignancy presented with seizures (19.4%). This result was far more than reported by Gilbert and Grossman (4%) and Clouston *et al.* (4.5%). A higher incidence of seizure in our patient population may be due to the fact that patients with seizures were more likely to be referred to a neurology facility for further management vis-à-vis to a non-neurological setting.\[[@ref1][@ref3][@ref6]\] We also found sphincter disturbances (bowel or bladder) in a higher proportion of patients (34.8%) as opposed to 2.1% (Clouston *et al.*); a disproportionately high incidence of sphincter involvement (96%) has also been reported from Pakistan.\[[@ref3][@ref16]\]

The most common site of malignancies overall was the brain (49.7%; primary and secondary included). A large proportion of patients had involvements of multiple sites, either vertebral or intracranial or both (23.9%), indicating the advanced stage at which first manifestations of malignancy were presented to us. Gilbert *et al.* reported epidural spinal compression in a marginally higher number of patients than the brain (primary and metastases) followed by plexus involvement.\[[@ref1]\] Kori *et al.* reported 0.43% of patients with malignancies having brachial plexopathy.\[[@ref17]\] Jaeckel reported nearly 15% of patients with malignancies initially presented with lumbosacral plexopathy.\[[@ref18]\] A peripheral nervous system including peripheral nerves may be involved in 1.6%--17% of patients with malignancies.\[[@ref19][@ref20]\] Clouston *et al.* reported 18.6% of patients with brain metastasis (including skull base metastases).\[[@ref3]\] This demonstrates the glaring difference between the presentation of malignancies in neurology versus oncology settings.

Even though our cohort was younger, those with secondary malignancies were in the higher age group (55 versus 40 years). Based on the age at the presentation, the geriatric group (≥65 years) is more likely to present with delirium, neurocognitive deficits, stroke and movement disorders while the non-geriatric group (\<65 years) more often presents with headache, seizures and cranial nerve involvement (especially visual disturbances).\[[@ref21]\] One must always be aware of hypoactive delirium that may mask as depression in this vulnerable geriatric population.\[[@ref22]\] Non-thyroid, urologic, skin and gastrointestinal malignancies have been reported to be significantly higher in the geriatric group while ovarian and haematological malignancies are common in the non-geriatric age group. These findings can help in planning the battery of investigations, prioritizing one over the other, as appropriate.\[[@ref11]\]

Imaging revealed a higher number of intra-axial lesions (59.4%) as compared to extra-axial (38.1%) with the most common imaging diagnosis in the intra-axial group being intracranial metastases and glioblastoma multiforme amongst primary tumours. Vertebral metastases among secondary malignancies and meningioma among primary tumours were the most common imaging diagnosis in the extra-axial group. Le Chevalier *et al.* noted multiple metastases in the brain in two-thirds of patients in their series. Approximately 10--15% of autopsies reveal intracranial metastatic lesions signifying their asymptomatic seeding in brain parenchyma.\[[@ref15]\] Kohler *et al.*, however, reported glioblastoma as the most common malignant and meningioma as the most common non-malignant tumour in adults.\[[@ref7]\] A Chinese study also noted that multiple metastases account for nearly three-fourths of the total brain metastases.\[[@ref23]\] A study from Pakistan, in an oncology setting reported 59.3% of patients having brain metastases with nearly 60% of them having multiple metastases.\[[@ref16]\] The reason for the higher proportion of multiple intracranial metastases (84%) in our and other studies seems to be the better detection rate as a result of MRI and increased survival with better management modalities.

It has been reported that 15--50% of patients with metastases end up with an undiagnosed primary despite an extensive work-up.\[[@ref15][@ref24]\] We could not find primary site of malignancy in 1 in 10 cases (6.4%) which were labelled carcinoma with unknown primary \[[Table 5](#T5){ref-type="table"}\]. Ante-mortem histopathological confirmation could be achieved in 38.1% of our patients. A higher histopathological confirmation rate; 60% and 44.2% have been reported by Merchut and Le Chevalier *et al.*, respectively.\[[@ref15][@ref25]\] With recent advances in imaging, different groups have studied the predictive value of whole body CT, positron-emission CT (PET-CT), and PET-MRI in their respective settings; they recommend initial use of these techniques to increase the yield of cancer detection.\[[@ref26][@ref27][@ref28]\] Overall, PET-CT appears to be a reasonable choice depending on the availability and cost constraints, especially in patients presenting with solitary lesions.\[[@ref29]\]

###### 

Primary origin of metastases

  A\) Definite (histopathologically confirmed)   
  ---------------------------------------------- ------------
  Lung                                           15
  Plasma cell                                    12
  Prostate                                       5
  Breast                                         4
  Genitourinary                                  5
  Thyroid                                        3
  Gastrointestinal                               1
  Head and neck                                  1
  Unknown                                        10
                                                 
  **B) Probable (as defined in the text)**       
                                                 
  **Primary tissue of origin**                   **Number**
                                                 
  Lung                                           12
  Plasma cell                                    3
  Gastrointestinal                               2
  Genitourinary                                  1
  Head and neck                                  1

The neuro-oncology register in the Netherlands reported lung, breast and prostate as the most common sites of primary cancer (in that order) causing metastases. Merchut reported lung as the most common primary followed by gastrointestinal tumours.\[[@ref25]\] Le Chevalier *et al.* found melanoma to be the second after lung cancer.\[[@ref14]\] Jin *et al.* reported an unknown primary followed by gastrointestinal tumours as the second and third most common tumours after lung.\[[@ref16]\] Van de Pol *et al.* reported an unknown primary and breast as the second and third most common sites, respectively.\[[@ref30]\] Barnholtz *et al.* reported melanoma and renal carcinoma as the next common sources of metastases in that order after lung.\[[@ref31]\] Our finding falls in line with the reported literature.

Surprisingly, in our study, plasma cell dyscrasias (22%; 10: multiple myeloma, 2: solitary plasmacytoma) was the second most common diagnosis followed by adenocarcinoma prostate in the third place (9%). This is a novel finding as earlier series have reported a minuscule proportion (approximately 1%) of their patients having myeloma (9 out of 855; 77 out of 7004).\[[@ref3][@ref32]\] A higher index of suspicion for plasma cell dyscrasias must be kept while evaluating patients with suspected metastases. Nerve conduction studies in these patients, might unmask the underlying radiculo-neuropathy, especially in the elderly age group.

We did not find a high number of carcinoma breast patients (four patients), being a neurology referral facility, as compared to those reported in the literature. Hovestadt *et al.* reported that patients with breast cancer have a high referral index, almost twice as that of lung cancer for complications.\[[@ref32]\] If we compare the age-standardized incidence rates of breast cancer per 100,000 population, India (25.8) has a significantly lower incidence when compared with the world average (43.1) and other parts of the world such as Europe (69.9), Canada (79.8), European Union (80.3) and Northern America (91.6).\[[@ref33]\]

There were a few limitations to our study. Based on the evaluation protocol, only admitted patients were considered for inclusion in this study; owing to the low socio-economic profile of a majority of patients the complete battery of investigations planned as per protocol could not be completed. Post-mortem analysis is not done at our centre whereby patients with an undiagnosed primary could not be evaluated further.

Conclusion {#sec1-5}
==========

Regarding neurological consultations with an unknown primary, organ-specific targeted efforts based on clinical evaluation for systemic localisation must be directed at diagnosing the primary. PET-CT may come handy in such situations. Besides providing an overview of malignancies primarily presenting with a neurological symptom, our study calls for a concerted effort in making a neuro-oncology register to aid early detection and timely initiation of therapy.
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